Logo

Krazati

BMS Touts Significant Growth in Breyanzi Revenues in Q1 as Overall Revenues Drop
Premium

The firm reported a 6 percent decrease in Q1 2025 revenues to $11.2 billion compared to $11.87 billion last year.

In Cancer Resistance Battle, Drugmakers' Arsenal Contains Combo Drugs, Common Biomarkers, ctDNA
Premium

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before first-generation therapies hit the market.

Krazati, Keytruda Score Median Progression-Free Survival of 27 Months in First-Line NSCLC
Premium

BMS is already testing the combo against just Keytruda as a first-line treatment in a Phase III trial in KRAS G12C-mutant and PD-L1-high tumors.

Focus on Primary Resistance May Improve KRAS Inhibitor Strategies in Colorectal, Pancreatic Cancer
Premium

The presence of primary resistance and KRAS G12C co-mutations may explain limited single-agent efficacy of marketed KRAS inhibitors, a recent study suggests.

Bristol Myers Squibb Focused on Opdivo SubQ Growth as Q4 Precision Product Sales Increase
Premium

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

Oct 31, 2024

BMS Anticipates New Opdivo Formulation Approval as CAR T, Targeted Therapy Sales Jump in Q3
Premium

Sep 18, 2024

Amgen's Lumakras Combo Scores High Response Rate in First-Line KRAS-Mutant Colorectal Cancer
Premium

Sep 15, 2024

Bristol Myers Squibb's Krazati Bests Chemo in KRAS-Mutant NSCLC With Brain Metastases
Premium

Aug 9, 2024

BMS Receives FDA Letter for Misleading Claims About Krazati's Efficacy in Promotional Material

Jul 26, 2024

BMS Reports 53 Percent Increase in Q2 Breyanzi Sales
Premium

Jun 21, 2024

FDA Approves BMS's Krazati With Cetuximab for KRAS G12C-Mutated Colorectal Cancer

May 15, 2024

Jacobio Pharma to Seek Approval in China for Glecirasib in KRAS-Mutant NSCLC After Phase II Readout
Premium

Apr 25, 2024

BMS Advancing Key Cancer Assets as Growth Portfolio Revenue Jumps 8 Percent in Q1
Premium

Apr 11, 2024

Boundless Bio Begins Phase I/II Trial of BBI-825 in Patients With Resistance Gene Amplifications

Apr 8, 2024

BMS's Krazati, Erbitux Combo Shows Potential as Standard Therapy in KRAS-Mutant Colorectal Cancer
Premium

Feb 20, 2024

Bristol Myers Squibb Seeking Approval for Krazati, Erbitux in KRAS G12C-Mutant Colorectal Cancer

Jan 10, 2024

Mirati Therapeutics' Krazati Approved in Europe for KRAS G12C-Mutant NSCLC

Nov 10, 2023

CHMP Reverses Prior Opinion, Recommends Approval for Mirati's Krazati in KRAS-Mutant NSCLC

Nov 6, 2023

UK's MHRA Conditionally Approves Mirati's Krazati for Advanced KRAS-Mutated NSCLC

Nov 2, 2023

Kura Oncology, Mirati Partner to Study KO-2806 With Krazati in KRAS-Mutant NSCLC

Oct 26, 2023

BMS Focused on Diversifying Oncology Portfolio Beyond Immunotherapy With Acquisitions
Premium

Oct 20, 2023

Krazati-Keytruda Combo Boasts 63 Percent Response Rate in Frontline Lung Cancer Study at ESMO

Oct 9, 2023

Bristol Myers Squibb Scooping Up Mirati Therapeutics, KRAS Inhibitor in $4.8B Deal

Sep 14, 2023

Krazati Two-Year Analysis Provides Insight Into Longer-Term Efficacy, Safety in KRAS-Mutant NSCLC
Premium

Aug 9, 2023

Mirati Therapeutics Prices Offering of Common Stock Expecting to Bring in $300M